Skip to main content
Fig.5 | Journal of Nanobiotechnology

Fig.5

From: Mesoporous silica nanoparticle-encapsulated Bifidobacterium attenuates brain Aβ burden and improves olfactory dysfunction of APP/PS1 mice by nasal delivery

Fig.5

Nasal instillation of MSNs-Bi reduced Aβ deposition and neuroinflammation in APP/PS1 mice. a Changes in blood Aβ levels in APP/PS1 mice treated with PBS, MSNs, Bifidobacterium, and MSNs-Bi at 1, 2, and 3 months after the first treatment. Bi refers to Bifidobacterium. Expression levels of anti-inflammatory factors IL-2, IL-4, and IL-10 b and pro-inflammatory factors IL-17A, TNF-α, and IL-6 (c) in the blood of APP/PS1 mice treated with PBS, MSNs, Bifidobacterium, and MSNs-Bi for 1 month. d Representative confocal images of APP/PS1 mouse brain sections treated with PBS, MSNs, Bifidobacterium, and MSNs-Bi; scale bar = 500 µm. e, f Percentage area fraction and the number of ThioS-positive Aβ plaques in the hippocampus and cortex of APP/PS1 mice treated with PBS, MSNs, Bifidobacterium, and MSNs-Bi for 1 month. g Representative confocal images of three-dimensional reconstruction of the cortex, depicting Aβ (grey) phagocytosed by IBA-1+ microglia (red); scale bar = 30 µm; Bi refers to Bifidobacterium. Data are presented as mean ± SD. Two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page